基于 RBD 蛋白的低成本 IgG ELISA 检测试剂盒用于 COVID-19 的开发和评估。
Development and evaluation of a low cost IgG ELISA test based in RBD protein for COVID-19.
机构信息
Instituto de Agrobiotecnología y Biología Molecular (IABIMO), UEDD INTA-CONICET, CICVyA, Instituto Nacional de Tecnología Agropecuaria (Institute of Biotechnology, NationalInstitute of AgriculturalTechnology), Argentina.
Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Departamento de Bioquímica Clínica, Cátedra de Microbiología Clínica, Argentina; Universidad de Buenos Aires, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Argentina.
出版信息
J Immunol Methods. 2022 Jan;500:113182. doi: 10.1016/j.jim.2021.113182. Epub 2021 Nov 8.
Serology tests for SARS-CoV-2 have proven to be important tools to fight against the COVID-19 pandemic. These serological tests can be used in low-income and remote areas for patient contact tracing, epidemiologic studies and vaccine efficacy evaluations. In this study, we used a semi-stable mammalian episomal expression system to produce high quantities of the receptor-binding domain-RBD of SARS-CoV-2 in a simple and very economical way. The recombinant antigen was tested in an in-house IgG ELISA for COVID-19 with a panel of human sera. A performance comparison of this serology test with a commercial test based on the full-length spike protein showed 100% of concordance between tests. Thus, this serological test can be an attractive and inexpensive option in scenarios of limited resources to face the COVID-19 pandemic.
血清学检测已被证明是对抗 COVID-19 大流行的重要工具。这些血清学检测可用于低收入和偏远地区进行患者接触追踪、流行病学研究和疫苗效果评估。在本研究中，我们使用半稳定的哺乳动物附加体表达系统，以简单且经济的方式大量生产 SARS-CoV-2 的受体结合域-RBD。重组抗原用人血清组进行了内部 IgG ELISA 检测。与基于全长刺突蛋白的商业检测的性能比较表明，两种检测方法的一致性为 100%。因此，在资源有限的情况下，这种血清学检测可以成为一种有吸引力且经济实惠的选择，以应对 COVID-19 大流行。
Zotero 插件